Healthcare Professionals
The Oncotype DX Colon Cancer Assay is clinically validated for recurrence risk in both Stage II and Stage III colon cancer.
The Oncotype DX Colon Cancer Assay is a 12-gene assay that provides an individualized score reflective of the risk of colon cancer recurrence for individual patients with Stage II or Stage III colon cancer. This quantitative information about colon cancer recurrence risk, based on the biology of a patient’s specific tumor, may help to inform individualized adjuvant treatment decisions in patients with Stage II or Stage III colon cancer.